The combination of the anti-LAG-3 monoclonal antibody Relatlimab and the anti-PD-1 antibody nivolumab has been shown to prolong progression-free survival (PFS) compared with PD-1 inhibition alone in patients with previously untreated melanoma.467 The combination of immune checkpoint inhibitors with targeted therapies is frequently utilized in clinical practice and can target tumor cells while alleviating tumor-mediated immunosuppression, thereby activating immune system functions. Here, LAG3 is linked to neoplasm.